BIOMARIN PHARMACEUTICAL INC Available-for-sale Securities, Amortized Cost Basis
BIOMARIN PHARMACEUTICAL INC (BMRN) had Available-for-sale Securities, Amortized Cost Basis of $1.65 billion as of 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-08-03
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $1.65B.
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $1.70B.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $1.79B; Available-for-sale Securities, Amortized Cost Basis as first filed $1.23B.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $1.24B.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-06-30 | $1.65B 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $1.70B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $1.79B 10-Q · filed 2018-08-03 | $1.23B 10-K · filed 2018-02-26 |
| 2017-09-30 | $1.24B 10-Q · filed 2017-10-31 | |
| 2017-06-30 | $858.36M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $865.42M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $971.23M 10-K · filed 2018-02-26 | $956.63M 10-K · filed 2017-02-27 |
| 2016-09-30 | $689.48M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $397.16M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $499.55M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $622.21M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $756.55M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $751.20M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $331.82M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $167.83M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $717.25M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $495.46M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $498.97M 10-Q · filed 2014-05-02 | |
| 2013-12-31 | $483.63M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $328.43M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $346.26M 10-Q · filed 2013-07-29 | |
| 2013-03-31 | $370.79K 10-Q · filed 2013-04-29 | |
| 2012-12-31 | $383.01M 10-K · filed 2014-02-26 | $386.01K 10-Q · filed 2013-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |